{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:55:36Z","timestamp":1790546136918,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"am","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE22Y7"],"award-info":[{"award-number":["GUIMBE22Y7"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HARRISG023"],"award-info":[{"award-number":["HARRISG023"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK72482"],"award-info":[{"award-number":["P30DK72482"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T16:46:28Z","timestamp":1749660388000},"page":"957-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0875-4750","authenticated-orcid":false,"given":"William T.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0600-4198","authenticated-orcid":false,"given":"Elizabeth H.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-8536","authenticated-orcid":false,"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Collaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-3767","authenticated-orcid":false,"given":"Michael S.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4052-1524","authenticated-orcid":false,"given":"Gabriela R.","family":"Oates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2025.05.002_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jcf.2025.05.002_bib0002","first-page":"3","article-title":"CFTR modulator therapies - effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2025.05.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.pulmoe.2023.03.008","article-title":"A real-life study of elexacaftor-tezacaftor-ivacaftor therapy in people with cystic fibrosis in Brazil","author":"Salomao","year":"2023","journal-title":"Pulmonology"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.002_bib0004","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jcf.2020.09.011","article-title":"Tobacco smoke exposure limits the therapeutic benefit of tezacaftor\/ivacaftor in pediatric patients with cystic fibrosis","volume":"20","author":"Baker","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.002_bib0005","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jcf.2024.07.010","article-title":"Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)","volume":"23","author":"Baker","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-062985","article-title":"Delivering a new future for people with Cystic Fibrosis","volume":"152","author":"Burgener","year":"2023","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.002_bib0007","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","article-title":"Update on clinical outcomes of highly effective modulator therapy","volume":"43","author":"Gifford","year":"2022","journal-title":"Clin Chest Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.002_bib0008","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a Clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.jcf.2025.05.002_bib0009","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMe1911602","article-title":"Realizing the dream of molecularly targeted therapies for Cystic fibrosis","volume":"381","author":"Collins","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2025.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.002_bib0011","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jcf.2021.06.014","article-title":"Cessation of smoke exposure improves pediatric CF outcomes: longitudinal analysis of CF Foundation Patient Registry data","volume":"20","author":"Oates","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.05.002_bib0012","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a National observational disease Registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc."},{"issue":"1","key":"10.1016\/j.jcf.2025.05.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2025.05.002_bib0014","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.002_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary exacerbations in adults with Cystic Fibrosis: a grown-up issue in a changing cystic fibrosis landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.jcf.2025.05.002_bib0016","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/ppul.24879","article-title":"Tobacco smoke exposure in pediatric cystic fibrosis: a qualitative study of clinician and caregiver perspectives on smoking cessation","volume":"55","author":"Oates","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00475-2020","article-title":"Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes","volume":"7","author":"Lam","year":"2021","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.002_bib0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2023.05.009","article-title":"Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Wang","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"18","key":"10.1016\/j.jcf.2025.05.002_bib0019","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.002_bib0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcf.2025.05.002_bib0021","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2025.05.002_bib0022","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.002_bib0023","first-page":"276","article-title":"The effectiveness and value of novel treatments for cystic fibrosis","volume":"27","author":"Tice","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"10.1016\/j.jcf.2025.05.002_bib0024","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for Cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.002_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2023.05.004","article-title":"Association of Pseudomonas aeruginosa infection stage with lung function trajectory in children with cystic fibrosis","volume":"22","author":"Rosenfeld","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2025.05.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00527-20","article-title":"Cigarette smoke exposure promotes virulence of Pseudomonas aeruginosa and induces resistance to neutrophil killing","volume":"88","author":"Chien","year":"2020","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.jcf.2025.05.002_bib0027","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jcf.2022.08.002","article-title":"Predicting risk-adjusted incidence rates of methicillin-resistant Staphylococcus Aureus and Pseudomonas Aeruginosa in cystic fibrosis programs in the United States","volume":"21","author":"Stoudemire","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.002_bib0028","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.002_bib0029","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2010.04.002","article-title":"Year-to-year changes in lung function in individuals with cystic fibrosis","volume":"9","author":"Liou","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74502-1","article-title":"Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry","volume":"10","author":"Earnest","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.002_bib0031","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.002_bib0032","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on annual rate of lung function decline in people with cystic Fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"20","key":"10.1016\/j.jcf.2025.05.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.jcf.2025.05.002_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph13101003","article-title":"The impact of secondhand smoke exposure on children with cystic fibrosis: a review","volume":"13","author":"Kopp","year":"2016","journal-title":"Int J Environ Res Public Health"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:26Z","timestamp":1779953726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325014717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325014717"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.05.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}